Literature DB >> 21667041

Defect in mevalonate pathway induces pyroptosis in Raw 264.7 murine monocytes.

Annalisa Marcuzzi1, Elisa Piscianz, Martina Girardelli, Sergio Crovella, Alessandra Pontillo.   

Abstract

The inhibition of mevalonate pathway by the aminobisphosphonate alendronate (ALD) has been previously associated with an augmented lipopolysaccharide-induced interleukin-1beta (IL-1β) secretion in monocytes, as demonstrated in an auto-inflammatory disease known as mevalonate kinase deficiency (MKD). In this study we investigated the effect of ALD + LPS on monocyte cell line (Raw 264.7) death. ALD strongly augmented LPS-induced programmed cell death (PCD) as well as IL-1β secretion in Raw murine monocytes, whereas necrosis was rather unaffected. ALD + LPS induced caspase-3 activation. Inhibition of IL-1β stimulation partially restored cell viability. These findings suggest that the inhibition of mevalonate pathway, together with a bacterial stimulus, induce a PCD partly sustained by the caspase-3-related apoptosis and partly by caspase-1-associated pyroptosis. The involvement of pyroptosis is a novel hit in our cell model and opens discussions about its role in inflammatory cells with chemical or genetic inhibition of mevalonate pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21667041     DOI: 10.1007/s10495-011-0621-1

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  11 in total

1.  The effect of clodronate on a mevalonate kinase deficiency cellular model.

Authors:  Valentina Zanin; Annalisa Marcuzzi; Elisa Piscianz; Josef Vuch; Anna Monica Bianco; Lorenzo Monasta; Giuliana Decorti; Sergio Crovella
Journal:  Inflamm Res       Date:  2012-08-01       Impact factor: 4.575

2.  Alendronate treatment induces IL-1B expression and apoptosis in glioblastoma cell line.

Authors:  Paola Maura Tricarico; Angeladine Epate; Fulvio Celsi; Sergio Crovella
Journal:  Inflammopharmacology       Date:  2017-06-23       Impact factor: 4.473

3.  Temperature and drug treatments in mevalonate kinase deficiency: an ex vivo study.

Authors:  Paola Maura Tricarico; Giulio Kleiner; Elisa Piscianz; Valentina Zanin; Lorenzo Monasta; Sergio Crovella; Annalisa Marcuzzi
Journal:  Biomed Res Int       Date:  2013-09-01       Impact factor: 3.411

Review 4.  Hyper-IgD syndrome/mevalonate kinase deficiency: what is new?

Authors:  C M Mulders-Manders; A Simon
Journal:  Semin Immunopathol       Date:  2015-05-20       Impact factor: 9.623

5.  Lovastatin dose-dependently potentiates the pro-inflammatory activity of lipopolysaccharide both in vitro and in vivo.

Authors:  Valentina Zanin; Annalisa Marcuzzi; Giulio Kleiner; Elisa Piscianz; Lorenzo Monasta; Serena Zacchigna; Sergio Crovella; Giorgio Zauli
Journal:  J Cardiovasc Transl Res       Date:  2013-12       Impact factor: 4.132

6.  Knockdown of MVK does not lead to changes in NALP3 expression or activation.

Authors:  Fulvio Celsi; Elisa Piscianz; Maurizio Romano; Sergio Crovella
Journal:  J Inflamm (Lond)       Date:  2015-01-31       Impact factor: 4.981

Review 7.  Clinical genetic testing of periodic fever syndromes.

Authors:  Annalisa Marcuzzi; Elisa Piscianz; Giulio Kleiner; Alberto Tommasini; Giovanni Maria Severini; Lorenzo Monasta; Sergio Crovella
Journal:  Biomed Res Int       Date:  2013-01-01       Impact factor: 3.411

8.  Lovastatin induces apoptosis through the mitochondrial pathway in an undifferentiated SH-SY5Y neuroblastoma cell line.

Authors:  A Marcuzzi; P M Tricarico; E Piscianz; G Kleiner; L Vecchi Brumatti; S Crovella
Journal:  Cell Death Dis       Date:  2013-04-11       Impact factor: 8.469

Review 9.  Mevalonate kinase deficiency and neuroinflammation: balance between apoptosis and pyroptosis.

Authors:  Paola Maura Tricarico; Annalisa Marcuzzi; Elisa Piscianz; Lorenzo Monasta; Sergio Crovella; Giulio Kleiner
Journal:  Int J Mol Sci       Date:  2013-11-26       Impact factor: 5.923

10.  Weekly oral alendronate in mevalonate kinase deficiency.

Authors:  Luca Cantarini; Antonio Vitale; Flora Magnotti; Orso Maria Lucherini; Francesco Caso; Bruno Frediani; Mauro Galeazzi; Donato Rigante
Journal:  Orphanet J Rare Dis       Date:  2013-12-20       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.